Thank you. Good link. I'm also not a fan of naked Ab but the abstract shows the value of preclinical study. With the mechanism of action and xenograft (human tumor in mouse) showing positive results, they could conceivably bring it back with better (synergistic) activity. I also would think ADC would make sense but that would mean starting the whole process over.
<<<<<I also would think ADC would make sense but that would mean starting the whole process over. >>>>>>>>
That's true but if results were very good as in SGN-35 they might shortcut the whole process with phase 1 followed by a pivotal phase 2/2b. Of course this is all hypothetical at this point but historically it worked out with SGN-30/35 The CD40 is a large target and could be vary lucrative. Time will tell.
<<<<Dacetuzumab is a humanized monoclonal antibody targeting the CD40 antigen, which is highly expressed on most B-lineage hematologic malignancies including multiple myeloma, non-Hodgkin lymphoma and chronic lymphocytic leukemia. CD40 is also found on many types of solid tumors, including bladder, renal and ovarian cancer and on cells that play a role in immunologic disorders.>>>>>